Business Wire

OnProcess Exceeds All Financial Expectations for FY21-22 and Drives Forward on a Circular Mission

Share

OnProcess Technology, a global pioneer powering the world’s circular service value chains, today announced the results of its 2022 financial year to shareholders, reporting success across all four ‘pillars’ of the company’s strategy, and defining a new ‘digital first’ direction for the company.

From a financial perspective, OnProcess highlighted a very strong year, finishing well ahead of revenue expectations and EBITDA targets. It also reported a 109% growth in revenues from existing customers against the lowest churn rate for many years, and an increase in customer Net Promoter Score (NPS) to 57.6.

OnProcess also confirmed the closing of a substantial investment round which will be used to further boost the technology and product roadmap as well as developing new sales and marketing capabilities into new market sectors.

OnProcess also highlighted the development and launch of its flagship digital platform, OnProcess Agora™ during the financial year, along with the first new application built on it, Agora Recover™, aimed at digitalizing the returns process, improving customer experience and satisfaction levels, and setting the path towards more sustainable, circular service supply chains. OnProcess Agora now forms the basis of all new customer implementations and the new digitalization direction set by the company – a transformational approach that not only applies digital efficiency to its customers’ processes but entirely new ways of running those processes and delivering new end-customer experiences.

The company also revealed some of its plans for the new financial year 2022-23, highlighting new product offerings under development as well as expansion into new market segments. To help drive those product innovations, the company announced the appointment of its first Chief Product Officer. Other focus areas for FY23 would be to drive the continued adoption of the Agora platform from existing customer migrations as well as new customer and account growth. It also announced further investment in talent as well as cementing the company’s stance on diversity, equity, and inclusion (DEI) and a commitment around certain social responsibility initiatives on sustainability and circular economy metrics for the company as well as for its customers.

“I am immensely proud of what the OnProcess team has achieved this year and would like to thank all of them for their efforts in delivering what has been a very successful year for OnProcess,” said Oliver Lemanski, CEO of OnProcess. “We have surpassed every goal set against our transformational strategy and exceeded all financial targets, all with a backdrop of continued global uncertainty from the Covid-19 pandemic and supply chain challenges for our customers. A successful year by any measure, but perhaps even more importantly one that shows that our strategic path of a new ‘digital-first’ OnProcess, is indeed the right one.”

About OnProcess Technology , Inc.

OnProcess supplies technology and services that power the world’s circular service supply chains. Providing managed services and digital transformation expertise that streamlines processes, maximizes customer lifetime value, and improves ‘circular’ sustainability goals, OnProcess is a trusted advisor to many of the world’s leading computer, networking, med-tech, wireless, telecommunications, and IT companies.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Marta Marinova
OnProcess Technology, Inc.
mmarinova@onprocess.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye